Gerard Pereira

Gerard is the Founder of Cortene, where he developed Cortene’s theory on the cause of ME/CFS and novel therapeutic approach. Prior to Cortene, Gerard was Chief Business officer and Chief Financial Officer of Capnia, Inc., a company developing a drug-device combination product for migraine and allergies. Previously, he served as Vice-President of Business Development for NeurogesX, Inc., a company developing a topical therapeutic for the treatment of neuropathic pain. Gerard has extensive experience across several aspects of the drug development process, including regulatory affairs, small molecule and peptide manufacturing and formulation, clinical trials and fund-raising. Gerard earned his MBA from the Graduate School of Business at Stanford University, and his MSc. and BSc. in Engineering from the University of Bath, UK.